NIKKEI 225
27,501.37 +99.32 (+0.36%) HANG SENG
21,558.22 -400.14 (-1.82%) CRUDE OIL
75.69 -0.19 (-0.25%) GOLD FUTURES
1,929.30 -1.50 (-0.08%) DOW
34,053.94 -39.02 (-0.11%) BTC-GBP
19,273.53 -391.07 (-1.99%)
Apontis Pharma AG (APPH.F)
- EQS Group
APONTIS PHARMA extends portfolio for the treatment of hypertension and hyperlipidemia by in-licensing a new Single Pill
EQS-News: APONTIS PHARMA AG / Key word(s): Product LaunchAPONTIS PHARMA extends portfolio for the treatment of hypertension and hyperlipidemia by in-licensing a new Single Pill 31.01.2023 / 07:30 CET/CESTThe issuer is solely responsible for the content of this announcement.APONTIS PHARMA extends portfolio for the treatment of hypertension and hyperlipidemia by in-licensing a new Single Pill New Single Pill with potential peak sales of approx. EUR 1.3 million Market launch already planned for mid
- EQS Group
APONTIS PHARMA: Number of announced market launches increases to ten Single Pills – Portfolio grows by two in-licensing deals
EQS-News: APONTIS PHARMA AG / Key word(s): Product LaunchAPONTIS PHARMA: Number of announced market launches increases to ten Single Pills – Portfolio grows by two in-licensing deals 29.11.2022 / 07:30 CET/CESTThe issuer is solely responsible for the content of this announcement.APONTIS PHARMA: Number of announced market launches increases to ten Single Pills – Portfolio grows by two in-licensing deals Continuous expansion of the Single Pill portfolio to meet the target of at least 20 Single Pil
- EQS Group
APONTIS PHARMA confirms 2022 forecast after successful nine-month period – Strong Single Pill pipeline to achieve medium-term targets
EQS-News: APONTIS PHARMA AG / Key word(s): 9 Month figures/Quarterly / Interim StatementAPONTIS PHARMA confirms 2022 forecast after successful nine-month period – Strong Single Pill pipeline to achieve medium-term targets 10.11.2022 / 07:30 CET/CESTThe issuer is solely responsible for the content of this announcement.APONTIS PHARMA confirms 2022 forecast after successful nine-month period – Strong Single Pill pipeline to achieve medium-term targets Superiority of Single Pill therapy confirmed in
